The lack of comprehensive studies directly impacts the development of effective treatments. Without a complete understanding of cancer biology, it is challenging to design drugs that target the disease precisely. For instance, the development of targeted therapies and immunotherapies relies heavily on detailed knowledge of cancer mechanisms, which comprehensive studies could provide.
Moreover, the absence of long-term data makes it difficult to assess the true efficacy and safety of new treatments. This can lead to situations where drugs appear effective in the short term but fail to provide lasting benefits or cause severe long-term side effects.
